Patents by Inventor Sebastien Gibot

Sebastien Gibot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MESENCHYMAL STEM CELLS OBTAINED FROM WHARTON'S JELLY FOR THE TREATMENT OF SEPSIS
    Publication number: 20240245732
    Abstract: The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: March 19, 2024
    Publication date: July 25, 2024
    Applicants: UNIVERSITÉ DE LORRAINE, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE NANCY
    Inventors: Danièle BENSOUSSAN, Sébastien GIBOT, Loïc REPPEL, Caroline LAROYE, Amir BOUFENZER, Léonore AVERCENC, Céline HUSELSTEIN
  • Mesenchymal stem cells obtained from Wharton's jelly for the treatment of sepsis
    Patent number: 11963984
    Abstract: The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: April 23, 2024
    Assignees: UNIVERSITÉ DE LORRAINE, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE NANCY
    Inventors: Danièle Bensoussan, Sébastien Gibot, Loïc Reppel, Caroline Laroye, Amir Boufenzer, Léonore Avercenc, Céline Huselstein
  • SOLUBLE TREM-1 AS A MARKER OF SEVERITY OR COMPLICATIONS FOR A SUBJECT SUFFERING FROM A CORONAVIRUS INFECTION
    Publication number: 20230273208
    Abstract: The use of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) as a marker in a method for identifying a subject suffering from a disease caused by a coronavirus such as COVID-19 at risk of having or developing a severe form and/or a complication or at risk of death, in a method for assessing the severity of a disease caused by a coronavirus such as COVID-19, and in a method for monitoring a subject suffering from a disease caused by a coronavirus such as COVID-19.
    Type: Application
    Filed: June 7, 2021
    Publication date: August 31, 2023
    Applicants: INOTREM, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE NANCY, UNIVERSITE DE LORRAINE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
    Inventors: Jean-Jacques GARAUD, Marc DERIVE, Margarita SALCEDO-MAGGUILLI, Lucie JOLLY, Sébastien GIBOT, David MOULIN, Mihai NETEA, Aline DE NOOIJER
  • Methods and kits for predicting the risk of having a cardiovascular disease or event
    Patent number: 10948498
    Abstract: A cardiovascular event or disease is prevented or treated in a subject by measuring the expression level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) level in a sample from the subject and comparing it to a reference level. Based on this comparison, subjects that are at risk of having or developing a cardiovascular event or disease are identified, and administered a suitable therapy.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: March 16, 2021
    Assignees: INOTREM, APHP (Assistance Publique-Hôpitaux de Paris), INSERM (Institut National de la Santé et de la Recherche Médicale), Université de Lorraine
    Inventors: Marc Derive, Sebastien Gibot, Hafid Ait-Oufella, Amir Boufenzer, Tabasomme Simon, Nicolas Danchin
  • THERAPEUTIC TREM-1 PEPTIDES
    Publication number: 20200254058
    Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
    Type: Application
    Filed: February 18, 2020
    Publication date: August 13, 2020
    Inventors: Gilbert FAURE, Sebastien GIBOT, Paola PANINA, Nadia PASSINI
  • Therapeutic TREM-1 peptides
    Patent number: 10603357
    Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
    Type: Grant
    Filed: December 14, 2015
    Date of Patent: March 31, 2020
    Assignees: Bristol-Myers Squibb Company, Universite de Lorraine
    Inventors: Gilbert Faure, Sebastien Gibot, Paola Panina, Nadia Passini
  • MESENCHYMAL STEM CELLS OBTAINED FROM WHARTON'S JELLY FOR THE TREATMENT OF SEPSIS
    Publication number: 20200000856
    Abstract: The disclosure relates to human mesenchymal stem cells from Wharton's jelly, a method for preparing them, and the therapeutic uses thereof, in particular for the treatment of sepsis and specifically septic shock. The treatment may involve the administration to a subject in need thereof a pharmaceutical composition including the human mesenchymal stem cells from Wharton's jelly and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: February 28, 2018
    Publication date: January 2, 2020
    Applicants: UNIVERSITÉ DE LORRAINE, CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE NANCY
    Inventors: Danièle BENSOUSSAN, Sébastien GIBOT, Loïc REPPEL, Caroline LAROYE, Amir BOUFENZER, Léonore AVERCENC, Céline HUSELSTEIN
  • Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof
    Patent number: 9815883
    Abstract: The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 14, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE DE LORRAINE
    Inventors: Sebastien Gibot, Marc Derive
  • Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (TREM-1) TREM-like transcript 1 (TLT-1) for treatment of cardiovascular diseases
    Patent number: 9657081
    Abstract: The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: May 23, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE LORRAINE
    Inventors: Sebastien Gibot, Amir Boufenzer, Hafid Ait-Oufella, Marc Derive
  • THERAPEUTIC TREM-1 PEPTIDES
    Publication number: 20160193288
    Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
    Type: Application
    Filed: December 14, 2015
    Publication date: July 7, 2016
    Inventors: Gilbert FAURE, Sebastien GIBOT, Paola PANINA, Nadia PASSINI
  • METHODS AND KITS FOR PREDICTING THE RISK OF HAVING A CARDIOVASCULAR DISEASE OR EVENT
    Publication number: 20160187352
    Abstract: The present invention relates to a method for diagnosing a cardiovascular event or disease in a subject by measuring sTREM-1 level in a sample.
    Type: Application
    Filed: August 8, 2014
    Publication date: June 30, 2016
    Inventors: Marc DERIVE, Sebastien GIBOT, Hafid AIT-OUFELLA, Amir BOUFENZER, Tabasomme SIMON, Nicolas DANCHIN
  • Therapeutic TREM-1 peptides
    Patent number: 9273111
    Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterized by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
    Type: Grant
    Filed: July 12, 2011
    Date of Patent: March 1, 2016
    Assignees: Universite de Lorraine, Bristol-Myers Squibb
    Inventors: Gilbert Faure, Sebastien Gibot, Paola Panina, Nadia Passini
  • Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof
    Patent number: 9255136
    Abstract: Polypeptide The present invention relates to polypeptides fragments derived from the protein TLT-1 have been isolated and are useful in pharmaceutical preparations used for the treatment of inflammatory conditions such as sepsis.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: February 9, 2016
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Lorraine
    Inventors: Sebastien Gibot, Marc Derive
  • INHIBITING PEPTIDES DERIVED FROM TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF
    Publication number: 20160015773
    Abstract: The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.
    Type: Application
    Filed: April 29, 2015
    Publication date: January 21, 2016
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), UNIVERSITE DE LORRAINE
    Inventors: Sebastien GIBOT, Marc DERIVE
  • INHIBITING PEPTIDES DERIVED FROM TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-1 (TREM-1) TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF
    Publication number: 20150232531
    Abstract: The present invention relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 2 and a function-conservative variant. The invention also relates to a peptide comprising at least 6 consecutive amino acid selected from the amino acid sequence SEQ ID NO: 1 or SEQ ID NO: 2 and a function-conservative variant for use in the treatment of a cardiovascular disease.
    Type: Application
    Filed: September 9, 2013
    Publication date: August 20, 2015
    Inventors: Sebastien Gibot, Amir Boufenzer, Hafid Ait-Oufella, Marc Derive
  • INHIBITING PEPTIDES DERIVED FROM TREM-LIKE TRANSCRIPT 1 (TLT-1) AND USES THEREOF
    Publication number: 20130029921
    Abstract: The present invention relates to polypeptides fragments derived from the protein TLT-1 and their uses for the treatment of inflammatory conditions and more particularly for the treatment of sepsis.
    Type: Application
    Filed: April 8, 2011
    Publication date: January 31, 2013
    Inventors: Sebastien Gibot, Marc Derive
  • THERAPEUTIC PEPTIDES AND METHOD
    Publication number: 20120015867
    Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
    Type: Application
    Filed: July 12, 2011
    Publication date: January 19, 2012
    Inventors: Gilbert FAURE, Sebastien Gibot, Paola Panina, Nadia Passini
  • Method of diagnosing infectious disease by measuring the level of soluble TREM-1 in a sample
    Patent number: 8021836
    Abstract: The present invention concerns a method of diagnosing disease of bacterial or fungal origin in a subject, which method comprises the step of measuring the level of Strem-1 in a biological sample obtained from said subject.
    Type: Grant
    Filed: January 27, 2005
    Date of Patent: September 20, 2011
    Assignee: Université Henri Poincaré-Nancy I
    Inventors: Marie Nathalie Kolopp-Sarda, Marie-Christine Bene, Paola Panina, Pietro Di Lucia, Bruno Levy, Pierre-Edouard Bollaert, Gilbert Faure, Sebastien Gibot
  • Therapeutic peptides and method
    Patent number: 8013116
    Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterized by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
    Type: Grant
    Filed: February 2, 2009
    Date of Patent: September 6, 2011
    Assignees: Universite Henri-Poincare-Nancy I, Novo Nordisk A/S
    Inventors: Gilbert Faure, Sebastien Gibot, Paola Panina, Nadia Passini
  • Therapeutic peptides and method
    Publication number: 20090253632
    Abstract: A polypeptide comprising one or more sequences derived from CDR2 or CDR3 of a TREM-1 protein, characterised by the ability to treat, ameliorate, or lessen the symptoms of conditions including sepsis, septic shock or sepsis-like conditions and IBD.
    Type: Application
    Filed: February 2, 2009
    Publication date: October 8, 2009
    Inventors: Gilbert Faure, Sebastien Gibot, Paola Panina, Nadia Passini